CDXI Relative Valuation - Cardax Inc

Watchlist Manager

Watchlist

Price: 0.0001 USD

Market Cap: $1

	Cardax Inc OTC:CDXI	US
W	Whoosh Holding PAO MOEX:WUSH	RU
A	Astra Exploration Inc XTSX:ASTR	CA
A	ALT Telecom PCL SET:ALT	TH
	Landmark Bancorp Inc NASDAQ:LARK	US

Relative Value

CDXI doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CDXI.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

CDXI Relative Value

Base Case

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
US		Cardax Inc OTC:CDXI	1 USD	0	-0	-1.2	-1.1
US		Eli Lilly and Co NYSE:LLY	856.7B USD	13.3	41.9	28.3	30.2
US		Johnson & Johnson NYSE:JNJ	566.8B USD	6	21.1	14.7	18.1
CH		Roche Holding AG SIX:ROG	243.3B CHF	3.9	18.6	11.1	12.5
UK		AstraZeneca PLC LSE:AZN	215.5B GBP	4.9	28	15.6	21.9
US		Merck & Co Inc NYSE:MRK	282.6B USD	4.4	15.7	9.7	11.8
CH		Novartis AG SIX:NOVN	221.8B CHF	5.1	20.6	12.8	16.4
IE	E	Endo International PLC LSE:0Y5F	237.1B USD	102.3	-81.1	375.3	941.3
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.3	7.6	8.9
US		Pfizer Inc NYSE:PFE	153.4B USD	2.4	19.6	7.6	10.1
US		Bristol-Myers Squibb Co NYSE:BMY	115.7B USD	2.4	16.4	7	8.6

				Revenue Growth	P/S to Growth
US		Cardax Inc OTC:CDXI	Average P/S: 13.5 0	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	13.3	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6	6%	1
CH		Roche Holding AG SIX:ROG	3.9	4%	1
UK		AstraZeneca PLC LSE:AZN	4.9	7%	0.7
US		Merck & Co Inc NYSE:MRK	4.4	5%	0.9
CH		Novartis AG SIX:NOVN	5.1	5%	1
IE	E	Endo International PLC LSE:0Y5F	102.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	2%	1.7
US		Pfizer Inc NYSE:PFE	2.4	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A

				Earnings Growth	PEG
US		Cardax Inc OTC:CDXI	Average P/E: 21.4 Negative Multiple: -0	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	41.9	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.1	7%	3
CH		Roche Holding AG SIX:ROG	18.6	14%	1.3
UK		AstraZeneca PLC LSE:AZN	28	26%	1.1
US		Merck & Co Inc NYSE:MRK	15.7	14%	1.1
CH		Novartis AG SIX:NOVN	20.6	14%	1.5
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -81.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.3	1%	10.3
US		Pfizer Inc NYSE:PFE	19.6	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.4	16%	1

				EBITDA Growth	EV/EBITDA to Growth
US		Cardax Inc OTC:CDXI	Average EV/EBITDA: 49 Negative Multiple: -1.2	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	28.3	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.7	2%	7.3
CH		Roche Holding AG SIX:ROG	11.1	6%	1.8
UK		AstraZeneca PLC LSE:AZN	15.6	13%	1.2
US		Merck & Co Inc NYSE:MRK	9.7	3%	3.2
CH		Novartis AG SIX:NOVN	12.8	5%	2.6
IE	E	Endo International PLC LSE:0Y5F	375.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.6	1%	7.6
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
US		Cardax Inc OTC:CDXI	Average EV/EBIT: 108 Negative Multiple: -1.1	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	30.2	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.1	6%	3
CH		Roche Holding AG SIX:ROG	12.5	6%	2.1
UK		AstraZeneca PLC LSE:AZN	21.9	21%	1
US		Merck & Co Inc NYSE:MRK	11.8	6%	2
CH		Novartis AG SIX:NOVN	16.4	9%	1.8
IE	E	Endo International PLC LSE:0Y5F	941.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.9	2%	4.5
US		Pfizer Inc NYSE:PFE	10.1	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.6	-7%	N/A

Cardax Inc
OTC:CDXI

Relative Value

Valuation Multiples

Multiples Across Competitors

CDXI Competitors Multiples
Cardax Inc Competitors

See Also

Company

Help

Tools

Stocks

Cardax Inc OTC:CDXI

Relative Value

Valuation Multiples

Multiples Across Competitors

CDXI Competitors Multiples Cardax Inc Competitors

See Also

Company

Help

Tools

Stocks

Cardax Inc
OTC:CDXI

CDXI Competitors Multiples
Cardax Inc Competitors